giikorea.co.kr
 È¨ | ȸ»ç¼Ò°³ | ¸ÂÃãÇü ½ÃÀåÁ¶»ç | ±¹Á¦ÄÁÆÛ·±½º | ±Û·Î¹ú ÆÄÆ®³Ê | īŻ·Î±× | E-mail Service | ¿¬¶ôó | Site Map

Conference banner
¿µ¾î ÀϺ»¾î TW
½ÃÀ庸°í¼­

ÁßÃ߽Űæ°è(CNS) Drug Discoveries µ¿Çâ : ¾ËÃ÷ÇÏÀ̸Ӻ´

CNS Drug Discoveries: Alzheimer's Disease

ÃâÆÇ»ç Espicom Business Intelligence Contact us : 02-2025-2992
ÃâÆÇÀÏ 2008/08
ÆäÀÌÁö  
º¸°í¼­ ÄÚµå 76133
°¡ °Ý £¤1,040 ÁÖ¹®°¡°Ý
£¤1,040 PDF By E-mail (Single User License)
£¤1,040 Hard Copy
Delivery Time
PDF by E-Mail
ÁÖ¹®ÈÄ 1-2ÀÏ ³»¿¡ Email·Î º¸³»µå¸³´Ï´Ù.
Hard Copy/CD-ROM
¿µ¾÷ÀÏ ±âÁØ 5-7ÀÏ ÀüÈÄ·Î ÀÚ·á ¼ö·ÉÀÌ °¡´ÉÇÕ´Ï´Ù.

¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ °¢Á¾ Ä¡·áÁ¦ °³¹ß µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí Ãâ½ÃµÈ ÁÖ¿ä Á¦Ç°ÀÇ »óȲ ¹× ¸Å»ó ½ÇÀû¡¤¿¹Ãø, °³¹ßÁßÀÎ Á¦Ç°ÀÇ »óȲ ¹× ÇâÈÄ ¸Å»ó ¿¹Ãø, ¾ËÃ÷ÇÏÀ̸Ӻ´°ú ȯÀÚ¿¡ °üÇÑ °¢Á¾ µ¥ÀÌÅÍ, Á¦Ç°¡¤±â¾÷ÀÇ °æÇÕ ºÐ¼® µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

    1. ¾ËÃ÷ÇÏÀ̸Ӻ´¿¡ ´ëÇÏ¿©
    2. Áúº´ °ü·Ã µ¥ÀÌÅÍ
    • ȯÀÚ Åë°è
    • ȯÀÚ ¸ðµ¨
    • ¾àÁ¦ ½ÃÀåÀÇ ¼ºÀå °ßÀÎ ¿äÀÎ
    • ¾àÁ¦ ½ÃÀåÀÇ ¼ºÀå¿¡ À־ÀÇ À§Ç衤À庮
    3. ¾ËÃ÷ÇÏÀ̸Ӻ´ ½ÃÀå
    • ÁÖ¿ä±â¾÷
    • ±â¾÷ ¹× Á¦Ç°
    4. ÇöÀçÀÇ Ä¡·áÁ¦
    • ÁÖ¿ä ºê·£µå ºÐ¼®
      • ¾Æ¼¼Æ¿Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦(Acetylcholinesterase) ÀúÇØÁ¦
        • Aricept
        • Exelon
        • Razadyne
      • NMDA Antagonist
        • Namenda/Ebixa
    • ¼¼°èÀÇ ¸Å»ó ¿¹Ãø : ÇöÀçÀÇ Ä¡·áÁ¦ : 2007-2014³â
    5. R&DÁßÀÎ ½Å¾à
    • ´Ü°èIII ÀǾàǰ
      • Bapineuzumab
      • Flurizan
      • LY450139
    • ¼¼°èÀÇ ¸Å»ó ¿¹Ãø : ÃÖÁ¾ ´Ü°è ¾àÁ¦ : 2011-2014³â
    • ´Ü°èII ÀǾàǰ
      • CX717
      • EVT 101
      • Ketasyn
      • MEM 1003
      • MEM 3454
      • PBT2
    6. °æÇÕ·ü ºÐ¼®
    • °æÇÕ·ü ºÐ¼® : Á¦Ç°
    • °æÇÕ·ü ºÐ¼® : ±â¾÷
    • ½ÂÀÚ¡¤ÆÐÀÚ
    7. °³¹ß ÁßÁöµÈ ÀǾàǰ
    8. ºÎ·Ï1 : ´Ü°è ÀÌÇàÀÇ °¡´É¼º
    9. ºÎ·Ï2 : ¾ËÃ÷ÇÏÀ̸Ӻ´ÀÇ È¯ÀÚ ¸ðµ¨
    10. ºÎ·Ï3 : ¼¼°èÀÇ ¾ËÃ÷ÇÏÀÌ¸Ó Ä¡·áÁ¦ ¸Å»ó : 2007-2014³â
    11. ºÎ·Ï4 : °æÇÕ·ü ºÐ¼® ±âÁØ
LSH
Related Reports

Back to Top


| Home | Contact | E-mailing | About GII | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§| Site Map |
(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼Ç
Tel:02-2025-2992, Fax:02-2025-2993, E-mail :
(C) Copyright 2009 Global Information, Inc. All rights reserved.